Market news

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

SELLAS Life Sciences is rated Hold, with a $9.25 price target, as the current valuation reflects REGAL trial success probability. Read more on SLS stock here.

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Monday's

Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...

Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]

Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.

A German report claimed Regal hit its 80th event, but Sellas has not confirmed it.

SELLAS Life Sciences Group, Inc. reported second-quarter 2026 results showing a net loss of US$9.61 million and basic loss per share from continuing operations of US$0.05, with first-half 2026 net loss reaching US$18.01 million and basic loss per share of US$0.10. Despite wider net losses in dollar terms, the company’s loss per share narrowed year on year, pointing to the impact of share count changes amid heightened interest in its Phase 3 GPS cancer vaccine program following positive...

SELLAS Life Sciences Group (SLS) is drawing fresh attention as investors reassess immune based cancer therapy stocks following Moderna and Merck’s Phase 3 cancer vaccine update and the broader oncology rally it helped spark. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.40, SELLAS Life Sciences Group has seen a 72.24% 90 day share price return and a very large 1 year total shareholder return. This suggests momentum has been building as attention shifts...

SELLAS Life Sciences Group stock has posted a very large 3 year return while the latest valuation checks flag it as expensive rather than a clear bargain. Over the past 3 years, SELLAS Life Sciences Group has delivered a gain of about 7.9x, which sets a high bar for any further upside to be justified. Progress toward key milestones in the REGAL AML trial and the advancement of SLS009 in difficult cancer indications can support high growth expectations, yet the usual risks around clinical...

Stergiou highlighted a Phase 2 study published in the Blood Advances journal that evaluated a maintenance therapy in 17 children with hard-to-treat acute leukemia following stem-cell transplants.

Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 20

In recent months, Daiwa Securities very sharply increased its stake in SELLAS Life Sciences Group by 100,300 shares, while SELLAS reported that its Phase 3 REGAL trial in acute myeloid leukemia had reached 78 of the 80 events required for final analysis and held an estimated US$138.30 million in cash at the end of June. This combination of an imminent pivotal trial readout and a strengthened institutional presence highlights how clinical and balance-sheet milestones are converging for...

SELLAS Life Sciences Group (SLS) is back in focus as its Phase 3 REGAL trial in acute myeloid leukemia nears final analysis and Daiwa Securities reports a very large increase in its shareholding. See our latest analysis for SELLAS Life Sciences Group. The recent clinical update and Daiwa’s larger stake come after a sharp move in SELLAS Life Sciences Group’s share price, with a 1-day share price return of 12.09% and a year-to-date share price return of 157.93%, while the 1-year total...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet its recent share price swings and a low overall value score suggest the stock may now be pricing in a lot of optimism. The stock has returned about 6.1x over the past 3 years, which sets a high bar for any further upside to be justified by fundamentals. Future clinical and commercial progress can support the current valuation, but execution risk and funding needs typical for early stage biopharma may limit how much...

3D Medicines wins HKIAC arbitration vs Sellas, securing HK$8M costs and clearing legal overhang.

CEO Angelos Stergiou said recently on “FOX & Friends” that AI and precision medicine could speed drug development and improve patient selection.

Shkreli reiterated his long-standing bearish stance on SLS, although he previously acknowledged making “a bad call” on Capricor after its positive HOPE-3 trial results.

Investors named Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly and Bristol Myers as possible bidders.

SELLAS Life Sciences Group (SLS) is drawing focused attention as its Phase 3 trial for galinpepimut-S in acute myeloid leukemia approaches the required events for an overall survival readout, a key catalyst for the stock. See our latest analysis for SELLAS Life Sciences Group. At a latest share price of $13.19, SELLAS Life Sciences Group has seen a 69.97% 1 month share price return and a 203.22% year to date share price return. The 1 year total shareholder return is very large, signaling that...

SELLAS Life Sciences Group has delivered a very large 3 year return, yet the stock currently screens as expensive on broad valuation checks. This sets up a clear tension between recent share price strength and what the fundamentals suggest about value. Over 3 years, the stock has returned close to 7x, which puts extra focus on whether that gain is supported by fundamentals or mainly by sentiment. Expectations for strong revenue and earnings growth, combined with a sizeable shelf registration...

Earlier this week, SELLAS Life Sciences Group highlighted that its REGAL Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia has reached 78 of the 80 required overall survival events, bringing the pivotal data readout within sight. Investor interest has also been shaped by amended executive employment agreements that include change-of-control benefits, feeding speculation about potential corporate developments alongside the awaited GPS results. With the REGAL Phase 3 GPS data...

Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover speculations and growing institutional interest. The company is expected to report data from the phase 3 study evaluating its Galinpepimut-S (GPS) treatment candidate in patients […]

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is one of the 10 Best Performing American Stocks in June 2026. On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm […]

CEO Angelos M. Stergiou addressed concerns over the company’s trial to treat acute myeloid leukemia.

SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading. SLS currently has no revenue, with all products in development or clinical trials, making the stock highly speculative. Technical indicators are overwhelmingly bullish, but high short interest highlights significant risk. Sentiment is...